Market Cap (In USD)
9.11 Million
Revenue (In USD)
1.64 Million
Net Income (In USD)
-3.43 Million
Avg. Volume
2096.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0101-0.0716
- PE
- -
- EPS
- -
- Beta Value
- -0.642
- ISIN
- AU000000BIT4
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D.
- Employee Count
- -
- Website
- https://www.biotron.com.au
- Ipo Date
- 2013-03-22
- Details
- Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
More Stocks
-
S5L
-
SWAGTAMSwagatam Trading & Services Li
SWAGTAM
-
TIPCO
-
002585
-
GRKP
-
HHR
-
WBGDWaraba Gold Limited
WBGD
-
5971